SCHEMBL2472907

SCHEMBL2472907

O=C(CCc1ccc(F)cc1)N1CCC(C(=O)NCc2ccccc2-c2ccccc2)(c2ccccc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.46
OPRL1 P41146 2/20 0.45
NAAA Q02083 1/20 0.45
FFAR1 O14842 2/20 0.43
FFAR4 Q5NUL3 2/20 0.43
USP19 O94966 2/20 0.43
EPHX2 P34913 1/20 0.43
ALDH1A1 P00352 1/20 0.42
GPR183 P32249 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
TACR1 P25103 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13183012 0.94 NAAA (0.48) OPRL1NAAAFFAR1FFAR4ALDH1A1
SCHEMBL10258507 0.92 GFER (0.44) GFERNAAAFFAR1FFAR4USP19
SCHEMBL2471516 0.88 OPRL1 (0.56) GFEROPRL1NAAAEPHX2ALDH1A1
SCHEMBL2513258 0.88 MEN1 (0.50) GFEROPRL1FFAR1EPHX2ALDH1A1
SCHEMBL2467799 0.87 OPRL1 (0.57) GFEROPRL1EPHX2ALDH1A1GPR183
SCHEMBL2467659 0.87 OPRL1 (0.57) GFEROPRL1EPHX2ALDH1A1GPR183
SCHEMBL14312423 0.85 GFER (0.43) GFERNAAAFFAR1FFAR4USP19
SCHEMBL2518322 0.84 OPRL1 (0.50) GFEROPRL1ALDH1A1TACR1KMT2A
SCHEMBL2470233 0.83 OPRL1 (0.52) GFEROPRL1EPHX2ALDH1A1TACR1
SCHEMBL2517917 0.83 OPRL1 (0.54) GFEROPRL1EPHX2ALDH1A1GPR183

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 GFER 1562/4885OPRL1 1904/4885NAAA 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.